Search Results - nikolaos+(nikos)+tapinos

4 Results Sort By:
Inhibition of the Egr2 promoter Antisense RNA with oligonucleotide GapmeRs as novel RNA therapy for human neuropathies
Overview Peripheral neuropathy can be caused by trauma, disease, or chemotherapy. We have developed sustained-release formulations that treat human neuropathies by prompting remyelination of the damaged nerves. The formulations are delivered by injection at the site of nerve damage, using a polymeric gel. Market Opportunity Peripheral nerve damage...
Published: 6/6/2024   |   Inventor(s): Nikolaos (Nikos) Tapinos, David Karambizi, Margot Moreno
Keywords(s):  
Category(s): Neurodegenerative Disease
Inhibition of FTO with Entacapone to Treat Glioblastoma
Overview Glioblastoma is one of the most aggressive and lethal human tumors. We are investigating the use of an FDA-approved drug, Entacapone, to treat glioma tumors. Market Opportunity Glioblastoma, one of the most aggressive forms of cancer, has a survival rate of only 14–15 months after diagnosis. There is an urgent need for effective therapies...
Published: 7/31/2024   |   Inventor(s): Nikolaos (Nikos) Tapinos, John Zepecki, David Karambizi
Keywords(s):  
Category(s): Oncology, Therapeutics
HDAC-7 as novel therapeutic target for human glioblastoma
Overview Glioblastoma is one of the most aggressive and lethal human tumors. We have identified histone deacetylase 7 (HDAC-7) as a potential therapeutic target, a crucial first step toward development of an effective treatment for glioblastoma. Market Opportunity Glioblastoma is the most malignant and aggressive primary brain tumor, with a survival...
Published: 8/8/2024   |   Inventor(s): Nikolaos (Nikos) Tapinos, Ola Hassan, David Karambizi
Keywords(s):  
Category(s): Therapy Targets, Oncology
Targeting enhancer RNAs (eRNA) for the treatment of primary brain tumors
­Novel Therapeutic Approach for Glioblastoma Overview Enhancer RNAs (eRNAs) are transcribed from active enhancer regions of the genome and function to increase the expression of target genes. The expression of specific eRNAs in glioma stem cells is correlated with decreased survival of patients with glioblastomas. Our novel technology uses synthetic...
Published: 10/25/2023   |   Inventor(s): Nikolaos (Nikos) Tapinos, Blessing Akobundu
Keywords(s):  
Category(s): Therapeutics, Oncology